En Es
Categorías

Fluidigm

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and diseas ...
Productos Covid-19Resumen
Close

Covid-19 Fluidigm

Laboratorio clínico

SARS-CoV-2 RT-PCR Assay
Advanta Dx SARS-CoV-2 RT-PCR Assay

The Advanta Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm proprietary microfluidics technology and the Juno and Biomark HD systems, enables reliable, high-capacity testing of saliva samples from patients suspected by their health care providers of COVID-19 (coronavirus) infection to support diagnostic decision making. The assay has been authorized for use under FDA Emergency Use Authorization (EUA) and is CE-IVD marked under the In Vitro Diagnostics Directive (IVDD 98/79/EC).
Mas detalles

RT-PCR Kit
Advanta RT-PCR Kit

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes. The kit enables probe-based qPCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
Mas detalles

SARS-CoV-2 Mutation Assay Panel
Advanta SARS-CoV-2 Mutation Assay Panel

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
Mas detalles
Close

Sobre Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide.

Actualizado

Real-Time PCR System
X9

The X9 Real-Time PCR System enables high data output with more than 9,000 individual nanoliter reactions in a single run, ensuring cost-effective comprehensive sample profiling with minimal operator contribution. The integration of multiple capabilities into a single platform streamlines workflows, offering practical use across a diverse array of applications.
Mas detalles

PLATAFORMA DE PCR EN TIEMPO REAL DE MICROFLUIDOS
Biomark X

Biomark X integra los instrumentos Fluidigm Juno y Biomark HD en una única plataforma agregando un amplio conjunto de capacidades de muestra a respuesta en una única plataforma genómica versátil, escalable y transformadora.
Mas detalles

PCR System
Biomark HD

Biomark HD is an automated, high-performance PCR system that uses microfluidics technology to process samples at nanoliter-scale volumes for gene expression, genotyping, sample identification, copy number variation analysis and digital PCR. Ideal for labs performing PCR on hundreds to thousands of samples, the Biomark HD provides significant cost and time advantages over alternate technologies. And with a wide range of integrated fluidic circuit (IFC) formats available, scaling from mid- to high throughput on a single system is easily achievable.
Mas detalles

Laboratorio clínico

Real-Time PCR System
X9

The X9 Real-Time PCR System enables high data output with more than 9,000 individual nanoliter reactions in a single run, ensuring cost-effective comprehensive sample profiling with minimal operator contribution. The integration of multiple capabilities into a single platform streamlines workflows, offering practical use across a diverse array of applications.
Mas detalles

PLATAFORMA DE PCR EN TIEMPO REAL DE MICROFLUIDOS
Biomark X

Biomark X integra los instrumentos Fluidigm Juno y Biomark HD en una única plataforma agregando un amplio conjunto de capacidades de muestra a respuesta en una única plataforma genómica versátil, escalable y transformadora.
Mas detalles

PCR System
Biomark HD

Biomark HD is an automated, high-performance PCR system that uses microfluidics technology to process samples at nanoliter-scale volumes for gene expression, genotyping, sample identification, copy number variation analysis and digital PCR. Ideal for labs performing PCR on hundreds to thousands of samples, the Biomark HD provides significant cost and time advantages over alternate technologies. And with a wide range of integrated fluidic circuit (IFC) formats available, scaling from mid- to high throughput on a single system is easily achievable.
Mas detalles

SISTEMA DE PERFIL INMUNOLÓGICO
Maxpar Direct Immune Profiling System

Maxpar Direct Immune Profiling System es la primera solución completa de muestra a respuesta para el perfil inmunológico de alta dimensión de PBMC humanas y sangre total. Cuenta con tecnología CyTOF en el sistema Helios.
Mas detalles

Mass Cytometer
CyTOF XT

CyTOF XT is the most technologically advanced mass cytometer to date, designed to build on the benefits of CyTOF technology while simplifying operation and automating sample acquisition for the best reproducibility and time to results from every run. CyTOF XT further enhances the capabilities of mass cytometry with workflow automation that simplifies sample processing and data acquisition. The instrument offers a new level of autonomy through streamlined operation, automatic monitoring and easier system management. The result is superior data quality—so you can focus on what matters most.
Mas detalles

SARS-CoV-2 Mutation Assay Panel
Advanta SARS-CoV-2 Mutation Assay Panel

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
Mas detalles

RT-PCR Kit
Advanta RT-PCR Kit

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes. The kit enables probe-based qPCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
Mas detalles

SARS-CoV-2 RT-PCR Assay
Advanta Dx SARS-CoV-2 RT-PCR Assay

The Advanta Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm proprietary microfluidics technology and the Juno and Biomark HD systems, enables reliable, high-capacity testing of saliva samples from patients suspected by their health care providers of COVID-19 (coronavirus) infection to support diagnostic decision making. The assay has been authorized for use under FDA Emergency Use Authorization (EUA) and is CE-IVD marked under the In Vitro Diagnostics Directive (IVDD 98/79/EC).
Mas detalles
Derecho de autor © 2000-2024 TradeMed.com. Todos los derechos reservados. | Términos y condiciones